NVAX (Novavax) Accumulated Depreciation : $0 Mil (As of Mar. 2025)

View and export this data going back to 1995. Start your Free Trial

What is Novavax Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Novavax's quarterly accumulated depreciation increased from Sep. 2024 ($0 Mil) to Dec. 2024 ($-49 Mil) but then stayed the same from Dec. 2024 ($-49 Mil) to Mar. 2025 ($0 Mil).

Novavax's annual accumulated depreciation increased from Dec. 2022 ($-47 Mil) to Dec. 2023 ($-75 Mil) but then stayed the same from Dec. 2023 ($-75 Mil) to Dec. 2024 ($-49 Mil).

Novavax Accumulated Depreciation Historical Data

The historical data trend for Novavax's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Accumulated Depreciation Chart

Novavax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-17.79

-25.80

-47.29

-74.97

-49.16

Novavax Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-	-	-	-49.16	-

Novavax Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Novavax Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Novavax's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Executives

James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100